Trial Profile
A Study in US Cystic Fibrosis Patients With the R117H-CFTR Mutation to Confirm the Long-term Safety and Effectiveness of Kalydeco, Including Patients <18 Years of Age, Combining Data Captured in the Cystic Fibrosis Foundation Registry From an Interventional Cohort and a Non-Interventional Cohort
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 04 Feb 2020 Status changed from active, no longer recruiting to completed.
- 31 Mar 2016 New trial record